Omeros Corporation

John E Bergmann

Hongkui Zeng

Neil S Cutshall

George A Gaitanaris

Rene Onrust

John Hohmann

Gregory A Demopulos

Patrick W Gray

Jennifer Lynn Gage

László Ürögdi

Linda Madisen

Vincent A Florio

Sándor Cseh

Fusheng Li

Demetri Vassilatis

Maria N Pavlova

Kellie L McIlwain

Derek Johnston

Ákos Papp

Alexander Gragerov

Lazlo Urogdi

Zeng Hongkui

The present invention provides GPCR polypeptides and polynucleotides, recombinant materials, and transgenic mice, as well as methods for their production. The polypeptides and polynucleotides are useful, for example, in methods of diagnosis and treatment of diseases and disorders. The invention also provides methods for identifying compounds (e.g., agonists or antagonists) using the GPCR polypeptides and polynucleotides of the invention, and for treating conditions associated with GPCR dysfunction with the GPCR polypeptides, polynucleotides, or identified compounds. The invention also provides diagnostic assays for detecting diseases or disorders associated with inappropriate GPCR activity or levels.

G protein coupled receptor 85 and SREB3 knockout mice and uses thereof

A method of treating a movement abnormality associated with the pathology of a neurological movement disorder, such as Parkinson's disease or Restless Leg(s) Syndrome by administering a therapeutically effective amount of a PDE7 inhibitory agent. An aspect of the invention provides for the administration of a PDE& inhibitory agent in conjunction with a dopamine agonist or precursor, such as levodopa. In another aspect of the invention, the PDE7 inhibitory agent may be selective for PDE7 relative to other molecular targets (i) known to be involved with the pathology of Parkinson's disease or (ii) at which other drug(s) that are therapeutically effective to treat Parkinson's disease act.

Use of PDE7 inhibitors for the treatment of movement disorders

Method of identifying a compound for the treatment or prevention of obesity

Compounds that inhibit PDE10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, Bell's palsy, cerebral palsy, sleep disorders, pain, Tourette syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. The compounds have the general structure: wherein m, n, p, x, R, R, R, R, R, R, A and B, are defined herein, including pharmaceutically acceptable salts, stereoisomers, solvates or prodrugs thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for inhibiting PDE10 in a warm-blooded animal in need of the same.

PDE10 inhibitors and related compositions and methods

Growing community of inventors

Mercer Island, WA, United States of America

John E Bergmann